X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (891) 891
Book Review (102) 102
Newsletter (81) 81
Publication (56) 56
Newspaper Article (11) 11
Magazine Article (10) 10
Conference Proceeding (6) 6
Dissertation (5) 5
Book Chapter (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rabeprazole (887) 887
index medicus (745) 745
humans (702) 702
male (546) 546
female (468) 468
omeprazole (406) 406
middle aged (396) 396
adult (392) 392
gastroenterology & hepatology (382) 382
proton pump inhibitors (378) 378
lansoprazole (280) 280
pharmacology & pharmacy (270) 270
2-pyridinylmethylsulfinylbenzimidazoles (246) 246
aged (241) 241
treatment outcome (229) 229
omeprazole - analogs & derivatives (208) 208
helicobacter infections - drug therapy (205) 205
helicobacter pylori (191) 191
anti-ulcer agents - administration & dosage (180) 180
drug therapy, combination (178) 178
proton pump inhibitor (175) 175
gastroesophageal reflux - drug therapy (163) 163
proton pump inhibitors - administration & dosage (159) 159
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (145) 145
esomeprazole (138) 138
benzimidazoles - administration & dosage (136) 136
anti-ulcer agents - therapeutic use (135) 135
gastroesophageal reflux (133) 133
omeprazole - administration & dosage (126) 126
medicine & public health (117) 117
gastroesophageal-reflux disease (113) 113
amoxicillin - administration & dosage (112) 112
drug administration schedule (111) 111
amoxicillin (107) 107
proton pump inhibitors - therapeutic use (106) 106
young adult (106) 106
cytochrome p-450 cyp2c19 (104) 104
prospective studies (102) 102
anti-bacterial agents - administration & dosage (100) 100
pharmacokinetics (98) 98
helicobacter pylori - drug effects (97) 97
pantoprazole (97) 97
infection (95) 95
hydrogen-ion concentration (94) 94
cross-over studies (93) 93
omeprazole - therapeutic use (93) 93
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use (92) 92
clarithromycin (90) 90
benzimidazoles - therapeutic use (89) 89
clarithromycin - administration & dosage (87) 87
rabeprazole - administration & dosage (86) 86
aryl hydrocarbon hydroxylases - genetics (85) 85
dose-response relationship, drug (85) 85
gastroenterology (85) 85
intragastric ph (84) 84
double-blind (83) 83
genotype (83) 83
time factors (81) 81
gastroesophageal reflux disease (78) 78
adolescent (77) 77
double-blind method (77) 77
dosage and administration (75) 75
care and treatment (74) 74
drug interactions (74) 74
eradication (73) 73
triple therapy (73) 73
gastric acid - secretion (72) 72
aged, 80 and over (70) 70
anti-bacterial agents - therapeutic use (70) 70
cyp2c19 (70) 70
therapy (69) 69
management (67) 67
proton pump inhibitors - adverse effects (67) 67
anti-ulcer agents - pharmacology (66) 66
efficacy (66) 66
gastric acidity determination (66) 66
metabolism (66) 66
hepatology (63) 63
internal medicine (63) 63
administration, oral (62) 62
drug therapy (62) 62
esophagitis (62) 62
research (62) 62
abridged index medicus (61) 61
analysis (61) 61
helicobacter-pylori infection (61) 61
cytochrome p-450 (60) 60
helicobacter infections - microbiology (60) 60
medical colleges (60) 60
oncology (60) 60
amoxicillin - therapeutic use (58) 58
benzimidazoles - pharmacology (57) 57
pharmacology/toxicology (57) 57
omeprazole - pharmacology (56) 56
enzyme inhibitors - administration & dosage (55) 55
japan (55) 55
animals (53) 53
proton pump inhibitors - pharmacology (53) 53
pharmacology (51) 51
metronidazole - administration & dosage (50) 50
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (938) 938
Russian (20) 20
Japanese (19) 19
Chinese (5) 5
French (3) 3
Korean (3) 3
Spanish (3) 3
German (2) 2
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Gastroenterology, ISSN 0002-9270, 07/2016, Volume 111, Issue 7, pp. 949 - 956
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 1, pp. 134 - 141
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2016, Volume 78, Issue 1, pp. 41 - 49
The Hedgehog pathway inhibitor vismodegib exhibits pH-dependent solubility, and in vitro studies have shown that vismodegib is a substrate of P-glycoprotein... 
Medicine & Public Health | CYP inhibitors | Clinical pharmacology | Oncology | Cancer Research | Pharmacology/Toxicology | Clinical drug–drug interaction | Pharmacokinetic | Proton-pump inhibitor | P-glycoprotein inhibitor | SINGLE | HUMAN PLASMA | ORAL ABSORPTION | MASS-SPECTROMETRY | GDC-0449 | ONCOLOGY | Clinical drug-drug interaction | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | HEDGEHOG SIGNALING PATHWAY | SOLID-PHASE EXTRACTION | Fluconazole - pharmacology | Proton Pump Inhibitors - pharmacology | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Pyridines - administration & dosage | Cytochrome P-450 CYP3A Inhibitors - pharmacology | Area Under Curve | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Fluconazole - administration & dosage | Solubility | Pyridines - pharmacokinetics | Anilides - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Itraconazole - pharmacology | Cytochrome P-450 CYP2C9 Inhibitors - administration & dosage | Cytochrome P-450 CYP2C9 Inhibitors - pharmacology | Drug Interactions | Anilides - administration & dosage | Proton Pump Inhibitors - administration & dosage | Rabeprazole - pharmacology | Female | Itraconazole - administration & dosage | Hydrogen-Ion Concentration | Rabeprazole - administration & dosage | Drug interactions | Cytochrome P-450 | Index Medicus | Original
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2013, Volume 12, Issue 2, pp. 131 - 140
Journal Article
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2013, Volume 38, Issue 9, pp. 1129 - 1137
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 11/2017, Volume 6, Issue 6, pp. 614 - 626
Palbociclib free base capsule is a weak base drug with highly pH‐dependent solubility. In vitro and in vivo studies evaluated the impact of acid‐reducing... 
free base capsule | pH‐dependent solubility | histamine‐2 receptor antagonist | acid‐reducing agent | local antacid | pharmacokinetics | fed condition | palbociclib | proton pump inhibitor | fast condition | pH-dependent solubility | acid-reducing agent | histamine-2 receptor antagonist | RABEPRAZOLE | INTRAGASTRIC ACIDITY | ANTICANCER AGENTS | KINASE 4/6 | MIXED MICELLES | BIOAVAILABILITY | SELECTIVE INHIBITOR | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | GASTRIC PH | DRUG-DRUG INTERACTIONS | Piperazines - administration & dosage | Proton Pump Inhibitors - pharmacology | Area Under Curve | Histamine H2 Antagonists - pharmacology | Pyridines - chemistry | Humans | Middle Aged | Bile Acids and Salts - chemistry | Pyridines - pharmacokinetics | Male | Piperazines - chemistry | Young Adult | Histamine H2 Antagonists - administration & dosage | Protein Kinase Inhibitors - chemistry | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Famotidine - administration & dosage | Micelles | Adult | Female | Piperazines - pharmacokinetics | Antacids - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Food-Drug Interactions | Solubility | Protein Kinase Inhibitors - administration & dosage | Rabeprazole - pharmacology | Famotidine - pharmacology | Antacids - administration & dosage | Hydrogen-Ion Concentration | Rabeprazole - administration & dosage | Acids | Pharmacology | Food | Index Medicus
Journal Article
Stroke, ISSN 0039-2499, 03/2015, Volume 46, Issue 3, pp. 722 - 731
BACKGROUND AND PURPOSE—There is controversy and little information about whether individual proton pump inhibitors (PPIs) differentially alter the... 
LANSOPRAZOLE | drug interactions | PROPENSITY SCORE | CARDIOVASCULAR EVENTS | CORONARY | OMEPRAZOLE | stroke | CLINICAL NEUROLOGY | pharmacoepidemiology | proton pump inhibitors | CONCOMITANT USE | platelet aggregation inhibitors | cohort studies | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | OUTCOMES | Medicaid | JAPANESE PATIENTS | ARTERY-DISEASE | Rabeprazole - adverse effects | Esomeprazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Male | Risk | Drug Therapy, Combination - adverse effects | Stroke - chemically induced | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Ticlopidine - administration & dosage | Female | Stroke - epidemiology | Retrospective Studies | Brain Ischemia - chemically induced | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Data Interpretation, Statistical | Stroke - prevention & control | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Proportional Hazards Models | Omeprazole - adverse effects | Brain Ischemia - prevention & control | Ticlopidine - analogs & derivatives | Lansoprazole - adverse effects | Aged | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Rabeprazole - administration & dosage | Index Medicus | Pharmacoepidemiology | Stroke | Drug interactions | Cohort studies | Platelet aggregation inhibitors | Proton pump inhibitors
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 6/2013, Volume 71, Issue 6, pp. 1635 - 1643
The metabolism of pazopanib is primarily mediated by CYP3A4. The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its... 
Medicine & Public Health | Ketoconazole | Esomeprazole | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | CYP3A4 | Pazopanib | RABEPRAZOLE | HEALTHY-SUBJECTS | 24-H | TRIAL | ONCOLOGY | PHARMACOLOGY & PHARMACY | INHIBITOR | PHASE-I | DRUG-INTERACTION | Neoplasms - metabolism | Proton Pump Inhibitors - pharmacology | Esomeprazole - administration & dosage | Cytochrome P-450 CYP3A | Ketoconazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Male | Ketoconazole - pharmacology | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Angiogenesis Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Pyrimidines - administration & dosage | Angiogenesis Inhibitors - pharmacokinetics | Sulfonamides - pharmacokinetics | Neoplasms - drug therapy | Cytochrome P-450 CYP3A Inhibitors | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Aged | Ketoconazole - adverse effects | Sulfonamides - administration & dosage | Care and treatment | Metabolites | Analysis | Cytochrome P-450 | Tumors | Antiulcer drugs | Index Medicus
Journal Article